

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**  
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

June 15, 2021  
Date of Report  
(Date of earliest event reported)

**BOQI INTERNATIONAL MEDICAL INC.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>000-50155</b> (Commission File Number)	<b>02-0563302</b> (IRS Employer Identification No.)
Room 3601, Building A, Harbour View Place, No. 2 Wuwu Road, Zhongshan District, Dalian, Liaoning Province, P. R. China, 116000 (Address of principal executive offices and zip code)		
(86) 0411 8220 9211 (Registrant's telephone number, including area code)		
Not Applicable (Former name or former address, if changed since last report)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common stock, \$0.001 par value	BIMI	NASDAQ Stock Market

---

**Item 8.01 Other Events.**

Following the Annual Meeting of Shareholders held on June 15, 2021, the Registrant's Board of Directors met and appointed the following independent directors to serve as members of the audit, nominating and compensation committees.

<b>Committee</b>	<b>Chair</b>	<b>Members</b>
Audit Committee	Mia Kuang Ching	Jianxin (Jason) Wang & Fengsheng Tan
Nominating Committee	Ju Li	Mia Kuang Ching & Jianxin (Jason) Wang
Compensation Committee	Fengsheng Tan	Ju Li & Jianxin (Jason) Wang

The Board of Directors also approved, effective June 15, 2021, that each independent director will be paid \$24,000 per annum for their service as a director of the Company.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 16, 2021

BOQI International Medical Inc.  
(Registrant)

By: /s/ Tiewei Song  
Tiewei Song  
Chief Executive Officer